U.S. Semiconductors Stock News

Key Insights EDAP TMS' significant individual investors ownership suggests that the key decisions are influenced by...

VAALCO Energy, Inc. recently reported that full-year 2025 sales volumes reached about 22,100 working interest barrels of oil equivalent per day, at the top of its guidance range, while production averaged approximately 21,150 working interest barrels of oil equivalent per day, landing near the midpoint of prior expectations. This combination of sales at the high end of guidance and production in line with targets suggests the company executed its 2025 operating plan efficiently and converted...

State Street (STT) has wrapped up FY 2025 with fourth quarter total revenue of US$3.7b and basic EPS of US$2.46, alongside trailing twelve month revenue of US$13.9b and EPS of US$9.55 that frame the full year earnings picture. Over recent periods, total revenue has moved from US$3.4b in Q4 2024 to US$3.5b in Q3 2025 and US$3.7b in Q4 2025, while quarterly EPS has ranged from US$2.07 in Q1 2025 to US$2.83 in Q3 2025 and US$2.46 in the latest quarter. With trailing net income of US$2.7b and a...

GSI Technology (GSIT) is back in focus after announcing a government funded proof of concept with G2 Tech for Sentinel, an autonomous perimeter security system that uses its Gemini-II APU for on-device AI inference. See our latest analysis for GSI Technology. The Sentinel announcement comes as interest in GSI Technology has picked up, with a 30 day share price return of 52.46% and a 1 year total shareholder return of 103.80%, suggesting momentum has been building recently on top of longer...

Earlier this month, CorMedix Inc. reshaped its leadership structure by naming CEO Joseph Todisco as Chairman of the Board, appointing Mike Seckler as EVP & Chief Commercial Officer, and issuing new 2026 revenue guidance of US$300 million to US$320 million. This combination of leadership consolidation, fresh commercial expertise, and quantified revenue expectations gives investors clearer insight into how CorMedix plans to run and grow the business. We’ll now examine how Todisco’s expanded...

If you are wondering whether Talen Energy's share price still reflects good value after a strong run, this article will walk through what the current market price might be implying. The stock closed at US$371.66, with returns of 0.2% over the last 7 days, 5.6% over the last 30 days, a 6.3% decline year to date, and 58.2% over the last year. This naturally raises questions about how much future upside or risk is already priced in. Recent company updates and sector news have kept attention on...

If you are wondering whether Group 1 Automotive's current share price reflects its true worth, this article walks through the numbers in a clear, practical way. The stock recently closed at US$395.06, with a 1 year return of an 11.3% decline, a 3 year return of 104.2% and a 5 year return of 161.4%, so recent moves look quite different depending on how far back you zoom. In the short term, returns over the last 7 days and 30 days, 1.9% and 3.1% declines respectively, contrast with the modest...

AIRO Group Holdings recently strengthened its balance sheet with US$83.70 million in cash and US$89.40 million in follow-on proceeds, easing near-term dilution concerns while continuing work on joint ventures, certifications and backlog conversion. What looks like routine execution, closing partnerships, securing approvals and turning backlog into revenue, could prove decisive in reshaping how the market views AIRO’s business quality. Next, we’ll examine how AIRO’s bolstered liquidity...

TSS, Inc. recently presented at the 28th Annual Needham Growth Conference at The Lotte New York Palace Hotel in New York, featuring Chief Financial Officer Daniel M. Chism and CEO, President & Director Darryll E. Dewan. This conference appearance gave management a high-visibility platform to communicate TSS’s business direction and priorities directly to a concentrated investor audience. We’ll now look at how investor expectations around TSS’s Needham conference presentation may influence...

If you are wondering whether Expeditors International of Washington at US$162.41 is offering good value right now, it helps to step back and look at what the current price might be implying. The stock has posted returns of 2.2% over the last 7 days, 8.5% over 30 days, 6.9% year to date, 49.0% over 1 year and 57.7% over 3 years, with a 5 year return of 83.4%. This naturally raises questions about how much of the story is already priced in. Recent attention on Expeditors has centered on its...

Scholar Rock recently outlined its 2026 plans around potential U.S. and European approvals and commercial launch preparations for apitegromab in spinal muscular atrophy, alongside ongoing clinical trials and leadership changes to support a move toward commercialization. An interesting angle is how Scholar Rock is extending apitegromab into younger SMA populations and facioscapulohumeral muscular dystrophy while scaling manufacturing and organizational capacity to support a broader...

Why Microvast’s New Finance Leadership Matters for Investors Microvast Holdings (MVST) has refreshed its senior finance team, naming interim finance lead Rodney Worthen as Chief Financial Officer and hiring former NextDecade executive Eric N. Garcia as Chief Accounting Officer. These appointments concentrate financial reporting, planning, and corporate development experience at the top of Microvast’s battery and energy storage business, which already reports annual revenue of US$444.5 million...

In December 2025, Federal Agricultural Mortgage completed a US$313.5 million securitization of agricultural mortgage loans, signaling continued investor appetite for its farm and rural credit exposure despite recent macro volatility. This transaction highlights how the company can recycle capital from its Farm & Ranch and related portfolios to support future lending capacity across rural America. Next, we’ll explore how this securitization and improving monetary conditions could influence...

Recent financial media coverage has pushed LexinFintech Holdings (LX) into the spotlight as a penny stock candidate, with attention centering on its fundamentals and its role within consumer finance during broader market volatility. See our latest analysis for LexinFintech Holdings. Despite the recent media spotlight, LexinFintech Holdings has faced pressure, with a 90 day share price return of a 40.12% decline and a 1 year total shareholder return of a 54.17% decline, suggesting momentum has...

Spire Global (SPIR) is back in focus after the company launched nine satellites on SpaceX's Twilight mission, including its HyMS weather sensor and eight satellites supporting Myriota's global IoT connectivity network. See our latest analysis for Spire Global. That satellite launch comes on the back of a sharp swing in sentiment, with a 72.51% 30 day share price return and a 55.06% year to date share price return, even though the 1 year total shareholder return is still a 32.65% decline. If...

Earlier this month, FuelCell Energy ended the employment of its Executive Vice President, General Counsel and Corporate Secretary Joshua Dolger without cause, and appointed Amanda J. Schreiber to those roles effective January 12, 2026. Schreiber’s extensive experience guiding complex power projects, governance, and risk management at ContourGlobal brings a power-sector-focused legal and compliance perspective to FuelCell Energy’s leadership team. Next, we’ll examine how Schreiber’s...

Latest Earnings Snapshot and How It Fits the Story Regions Financial (RF) has wrapped up FY 2025 with fourth quarter revenue of US$1,806 million and EPS of US$0.59, alongside trailing 12 month revenue of US$7.1 billion and EPS of US$2.31 that frame the full year picture. Over recent quarters the company has seen revenue move from US$1,660 million in Q1 2025 to US$1,811 million in Q3 2025, and EPS range between US$0.51 and US$0.62. This gives investors a clear line of sight on how the top line...

If you are wondering whether Ziff Davis is a bargain or a value trap at its current US$37.48 share price, you are not alone. The stock has returned 3.6% over the last 7 days and 4.8% over the last 30 days. Year to date it is at 10.3%, with a 31.8% decline over 1 year and a 56.1% decline over 3 years. These mixed returns sit against an ongoing stream of corporate updates and portfolio activity that continue to keep Ziff Davis on investors' watchlists. Together, these developments help explain...

Conference spotlight and why investors are watching LightPath Technologies (LPTH) is set to present at the 28th Annual Needham Growth Conference at The Lotte New York Palace Hotel in New York, and that upcoming appearance is drawing fresh attention from investors. See our latest analysis for LightPath Technologies. That conference appearance comes after a sharp run in the shares, with a 30 day share price return of 82.70% and a 1 year total shareholder return of 273.00%. This suggests...

If you are wondering whether AdaptHealth's share price lines up with its underlying worth, you are not alone. This article focuses squarely on what the current price might be implying about value. The stock last closed at US$10.61, with returns of 1.1% over 7 days, 1.2% over 30 days, 9.7% year to date and 0.9% over 1 year. These figures are set against much weaker 3 year and 5 year returns of 49.5% and 72.1% declines. Recent coverage has focused on AdaptHealth's position in the home...

BlackRock (BLK) has wrapped up FY 2025 with fourth quarter revenue of US$7.0b and basic EPS of US$7.26, while trailing 12 month figures show revenue of US$24.2b and EPS of US$35.83. Over recent periods, revenue has moved from US$20.4b in the trailing 12 months to Q4 2024 to US$24.2b by Q4 2025, with basic EPS shifting from US$42.45 to US$35.83 over the same comparison window. With trailing net profit margin at 22.9%, down from 31.2% a year earlier, the latest results pair solid top line...

Why Compass Therapeutics Is On Investors’ Radar Compass Therapeutics (CMPX) has drawn attention after recent share price moves, with the stock showing double digit returns over the past month and past 3 months despite reporting a net loss and no revenue. See our latest analysis for Compass Therapeutics. At a share price of $5.70, Compass Therapeutics has a 30 day share price return of 14.92% and a 90 day share price return of 33.80%. Its 1 year total shareholder return of 119.23% suggests...

Mereo BioPharma Group (NasdaqCM:MREO) has come into focus after releasing mixed Phase 3 results for setrusumab in osteogenesis imperfecta, along with a cash runway update to mid-2027 and progress on its alvelestat and vantictumab programs. See our latest analysis for Mereo BioPharma Group. The mixed Phase 3 readout and cash runway update come after a volatile stretch for the stock, with a 7 day share price return of 29.45% following a 30 day share price return decline of 66.67%, and a 1 year...

Rigel Pharmaceuticals (RIGL) has drawn fresh attention after launching a Phase 1b/2 trial combining REZLIDHIA with other therapies for acute myeloid leukemia and issuing full year 2026 revenue guidance of US$275 million to US$290 million. See our latest analysis for Rigel Pharmaceuticals. Despite the latest clinical update and 2026 revenue guidance, Rigel Pharmaceuticals’ recent share price performance has cooled, with a 7 day share price return of 8.23% and a 30 day share price return of...